✦ LIBER ✦

Human cancer and gene therapy

✍ Scribed by G. Schmidt-Wolf; I. G. H. Schmidt-Wolf

Publisher: Springer
Year: 1994
Tongue: English
Weight: 765 KB
Volume: 69
Category: Article
ISSN: 0939-5555
DOI: 10.1007/bf01696555

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gene therapy for human prostate cancer.

Gene therapy for human prostate cancer. Translational research in the hormone refractory dunning prostate cancer model

✍ Michael A. Carducci; Sujatha R. Ayyagari; Martin G. Sanda; Jonathan W. Simons 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 833 KB

Combination of oncolytic adenovirotherap

Combination of oncolytic adenovirotherapy and Bax gene therapy in human cancer xenografted models. Potential merits and hurdles for combination therapy

✍ Masayoshi Hioki; Shunsuke Kagawa; Toshiya Fujiwara; Ryo Sakai; Toru Kojima; Yuic 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 292 KB

## Abstract Cancer gene therapy and oncolytic virotherapy have been studied extensively. However, their clinical application is hampered by their weak anticancer activity. We previously constructed a replicating adenovirus (OBP‐301, Telomelysin), in which the human telomerase reverse transcriptase

p51/p63, a novel p53 homologue, potentia

p51/p63, a novel p53 homologue, potentiates p53 activity and is a human cancer gene therapy candidate

✍ Reiko Kunisaki; Shuntaro Ikawa; Toyoki Maeda; Yukoh Nakazaki; Ryo Kurita; Masami 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 551 KB

## Abstract ## Background p51 (p73L/p63/p40/KET), a recently isolated novel p53 homologue, binds to p53‐responsive elements to upregulate some p53 target genes and has been suggested to share partially overlapping functions with p53. p51 may be a promising candidate target molecule for anti‐cancer

Combination with CD/5-FC gene therapy en

Combination with CD/5-FC gene therapy enhances killing of human bladder-cancer cells by radiation

✍ Zhujun Zhang; Toshiro Shirakawa; Nobuyuki Hinata; Akira Matsumoto; Masato Fujisa 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 310 KB

## Abstract ## Background Resistance to radiation and chemotherapy is a significant obstacle to the treatment of advanced bladder cancer. Gene therapy combined with radiation represents a new approach to cancer treatment. In the present study, we investigated whether adenovirally directed, cytosin

The humoral response to the tumor-suppre

The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy

✍ Thierry Soussi 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 433 KB

Human osteocalcin: a strong promoter for

Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer

✍ Helen O. McCarthy; Jonathan A. Coulter; Jenny Worthington; Tracy Robson; David G 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 818 KB

## Abstract ## Background Gene therapy has been identified as a promising treatment strategy for hormone refractory prostate cancer (HRPC). We report, for the first time, the use of the human osteocalcin (hOC) promoter to control inducible nitric oxide synthase (iNOS) transgene expression in HRPC.